07:01 AM EDT, 10/31/2024 (MT Newswires) -- Merck ( MRK ) reported Q3 non-GAAP earnings Thursday of $1.57 per diluted share, down from $2.13 a year earlier.

Analysts polled by Capital IQ expected $1.57.

Sales for the quarter ended Sept. 30 were $16.66 billion, up from $15.96 billion a year earlier.

Analysts surveyed by Capital IQ expected $16.51 billion.

Merck ( MRK ) said it now expects 2024 non-GAAP EPS of $7.72 to $7.77, lower than the previous range of $7.94 to $8.04. Analysts polled by Capital IQ expect $7.95.

Sales for the year are projected to be $63.6 billion to $64.1 billion, narrower than the previous forecast of $63.4 billion to $64.4 billion. Analysts surveyed by Capital IQ expect $64.17 billion.

Price: 106.00, Change: +1.17, Percent Change: +1.12